Charles Schwab
SANA icon

Charles Schwab’s Sana Biotechnology SANA Stock Holding History

Charles Schwab’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.81M Buy
1,379,181
+13,033
+1% +$42K ﹤0.01% 2502
2026
Q1 		$3.93M Sell
1,366,148
-33,187
-2% -$131K ﹤0.01% 2498
2025
Q4 		$5.7M Buy
1,399,335
+126,772
+10% +$568K ﹤0.01% 2386
2025
Q3 		$4.52M Buy
1,272,563
+186,388
+17% +$674K ﹤0.01% 2485
2025
Q2 		$2.97M Buy
1,086,175
+19,871
+2% +$41K ﹤0.01% 2552
2025
Q1 		$1.79M Buy
1,066,304
+9,792
+0.9% +$27.4K ﹤0.01% 2649
2024
Q4 		$1.72M Buy
1,056,512
+8,666
+0.8% +$25.8K ﹤0.01% 2725
2024
Q3 		$4.36M Buy
1,047,846
+105,382
+11% +$554K ﹤0.01% 2443
2024
Q2 		$5.15M Buy
942,464
+118,954
+14% +$948K ﹤0.01% 2347
2024
Q1 		$8.24M Buy
823,510
+74,675
+10% +$559K ﹤0.01% 2079
2023
Q4 		$3.06M Buy
748,835
+17,519
+2% +$64.5K ﹤0.01% 2503
2023
Q3 		$2.83M Buy
731,316
+56,197
+8% +$302K ﹤0.01% 2494
2023
Q2 		$4.02M Buy
675,119
+104,299
+18% +$601K ﹤0.01% 2324
2023
Q1 		$1.87M Sell
570,820
-80,980
-12% -$324K ﹤0.01% 2542
2022
Q4 		$2.57M Buy
651,800
+16,931
+3% +$82.8K ﹤0.01% 2488
2022
Q3 		$3.81M Buy
634,869
+35,244
+6% +$254K ﹤0.01% 2364
2022
Q2 		$3.86M Sell
599,625
-12,428
-2% -$79.2K ﹤0.01% 2303
2022
Q1 		$5.06M Buy
612,053
+17,340
+3% +$140K ﹤0.01% 2275
2021
Q4 		$9.21M Buy
594,713
+11,916
+2% +$230K ﹤0.01% 2046
2021
Q3 		$13.1M Buy
582,797
+355,387
+156% +$7.46M ﹤0.01% 1854
2021
Q2 		$4.47M Buy
227,410
+58,914
+35% +$1.34M ﹤0.01% 2406
2021
Q1 		$5.64M Buy
+168,496
New +$5.49M ﹤0.01% 2238

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Charles Schwab's SANA Position: Q2 2026 in Review

Charles Schwab increased its Sana Biotechnology (SANA) stake by 0.95% in Q2 2026, buying an estimated $42K and bringing the position to 1,379,181 shares worth $4.81M. The position accounts for ﹤0.01% of the portfolio, ranked #2502.

Charles Schwab first reported a position in SANA in Q1 2021 and has held it in 22 quarters since. The position peaked at $13.1M in Q3 2021. 210 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

  • Charles Schwab held 1,379,181 shares of Sana Biotechnology worth $4.81M as of Q2 2026.
  • Charles Schwab bought 13,033 Sana Biotechnology shares in Q2 2026, an estimated $42K.
  • Sana Biotechnology made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2502 holding.
  • Charles Schwab first reported a position in Sana Biotechnology in Q1 2021 and has held it in 22 quarters since.
  • Charles Schwab's Sana Biotechnology position peaked at $13.1M in Q3 2021.
  • 210 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.